To the editor:
First of all, it is important to mention that Attorney John Healey established a nonprofit, 501(c)3 for Brent while battling stage 4 cancer. His kindness led to the formation of A.L.S. Northeast Trust, now located at 18 Center St., Newburyport. Many health care professionals, ALS patients and private individuals assisted in providing crucial information. We have worked privately and without resources for the past 12 years.
Carole Bergeron, R.N./hematology, has lovingly assisted me from the onset of Brent’s diagnosis. Six years into research, Carole woke up paralyzed and was diagnosed with M.S. Using much of the motor neuron research as a basis for her own treatment, she has fully recovered.
A special thank-you to the many health care professionals who either provided treatment or contributed research information: Victor Marcial-Vega, Miami Baptist, John Foster, M.D., Haverford A.L.S. Clinic, Tom Lahey, Lutimax for speech restoration, Dr. Mengqi Xiu, M.D., Terry Shintani, M.D., scalar technology and cellular restoration (thank you, Herb Crooks, for donating this technology for patients in this area), Betty Fuhr, Mt. Sinai Hospital, Dr. Pye, John Orava, physicist, and others too numerous to mention. Thank you also to the many ALS patients who assisted us in profiling information in response to my very primitive 2003 website, www.alsalternative.com. A special thanks in memory of Mark Chamberlain, ALS patient. Mark was a driving force on behalf of other patients who advocated for the same type of research we provided; simply test the patients; find the cause.
This research and clinical evidence was recently completed. A simple Sonogram has established that 100 percent of the A.L.S. patients (who volunteered to be tested) have advanced liver disease. Blood tests were found to be inaccurate. John Radcliffe Hospital (UK) has confirmed through MRI’s acute damage to the brain (ALS) due to gluten sensitivity. Approximately 20 percent of patients with ALS exhibit liver damage from cholesterol drugs (Northwestern U, 2006, “statin drugs may be a probable cause of ALS”). Yet, a clinical for patients was announced a few years ago indicating “Lipitor may be therapeutic in the treatment of ALS.” Tamoxifen, a breast cancer drug, is proposed for the next series of ALS clinicals. The drug has the potential to cause liver damage.